WO2004012735A3 - Nouveaux conjugues d'effecteurs, procedes permettant de les produire et utilisation pharmaceutique de ceux-ci - Google Patents

Nouveaux conjugues d'effecteurs, procedes permettant de les produire et utilisation pharmaceutique de ceux-ci Download PDF

Info

Publication number
WO2004012735A3
WO2004012735A3 PCT/EP2003/008483 EP0308483W WO2004012735A3 WO 2004012735 A3 WO2004012735 A3 WO 2004012735A3 EP 0308483 W EP0308483 W EP 0308483W WO 2004012735 A3 WO2004012735 A3 WO 2004012735A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
pharmaceutical use
conjugates
new effector
effector conjugates
Prior art date
Application number
PCT/EP2003/008483
Other languages
English (en)
Other versions
WO2004012735A2 (fr
Inventor
Markus Berger
Gerhard Siemeister
Ulrich Klar
Joerg Willuda
Andreas Menrad
Klaus Bosslet
Original Assignee
Schering Ag
Markus Berger
Gerhard Siemeister
Ulrich Klar
Joerg Willuda
Andreas Menrad
Klaus Bosslet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10234975A external-priority patent/DE10234975A1/de
Priority claimed from DE10305098A external-priority patent/DE10305098A1/de
Priority to EA200500223A priority Critical patent/EA200500223A1/ru
Priority to CA002492437A priority patent/CA2492437A1/fr
Priority to AU2003253365A priority patent/AU2003253365A1/en
Priority to YUP-2005/0082A priority patent/RS20050082A/sr
Priority to MXPA05001282A priority patent/MXPA05001282A/es
Priority to NZ537870A priority patent/NZ537870A/en
Application filed by Schering Ag, Markus Berger, Gerhard Siemeister, Ulrich Klar, Joerg Willuda, Andreas Menrad, Klaus Bosslet filed Critical Schering Ag
Priority to EP03743752A priority patent/EP1524979A2/fr
Priority to IL16603903A priority patent/IL166039A0/xx
Priority to BR0313043-6A priority patent/BR0313043A/pt
Priority to JP2005506073A priority patent/JP2006505627A/ja
Publication of WO2004012735A2 publication Critical patent/WO2004012735A2/fr
Publication of WO2004012735A3 publication Critical patent/WO2004012735A3/fr
Priority to IS7708A priority patent/IS7708A/is
Priority to NO20051038A priority patent/NO20051038L/no
Priority to HR20050186A priority patent/HRP20050186A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'invention concerne des conjugués d'épothilones et des dérivés d'épothilone (en tant qu'effecteurs) avec des biomolécules adéquates (en tant qu'unités de reconnaissance). Le procédé de production consiste à faire réagir les effecteurs avec des lieurs appropriés ; les composés qui sont produits étant conjugués avec les unités de reconnaissance. La présente invention concerne également l'utilisation pharmaceutique de ces conjugués pour traiter des troubles prolifératifs ou associés à l'angiogenèse.
PCT/EP2003/008483 2002-07-31 2003-07-31 Nouveaux conjugues d'effecteurs, procedes permettant de les produire et utilisation pharmaceutique de ceux-ci WO2004012735A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BR0313043-6A BR0313043A (pt) 2002-07-31 2003-07-31 Conjugados efetores, processo para sua produção e seu uso farmacêutico
JP2005506073A JP2006505627A (ja) 2002-07-31 2003-07-31 新規エフェクター接合体、それらの生成方法及びそれらの医薬使用
EP03743752A EP1524979A2 (fr) 2002-07-31 2003-07-31 Nouveaux conjugues d'effecteurs, procedes permettant de les produire et utilisation pharmaceutique de ceux-ci
AU2003253365A AU2003253365A1 (en) 2002-07-31 2003-07-31 New effector conjugates, process for their production and their pharmaceutical use
YUP-2005/0082A RS20050082A (en) 2002-07-31 2003-07-31 New efector conjugates,process for their production and their pharmaceutical use
MXPA05001282A MXPA05001282A (es) 2002-07-31 2003-07-31 Conjugados efectores nuevos, procedimiento para su produccion y su uso farmaceutico.
NZ537870A NZ537870A (en) 2002-07-31 2003-07-31 New effector conjugates, process for their production and their pharmaceutical use
EA200500223A EA200500223A1 (ru) 2002-07-31 2003-07-31 Новые конъюгаты - эффекторы, способ их получения и их фармацевтическое применение
CA002492437A CA2492437A1 (fr) 2002-07-31 2003-07-31 Nouveaux conjugues d'effecteurs, procedes permettant de les produire et utilisation pharmaceutique de ceux-ci
IL16603903A IL166039A0 (en) 2002-07-31 2003-07-31 New effector conjugates process for their production and their pharmaceutical use
IS7708A IS7708A (is) 2002-07-31 2005-02-23 Tenglar fyrir stýrisameindir, efnasmíði þeirra oglyfjafræðileg notkun
HR20050186A HRP20050186A2 (en) 2002-07-31 2005-02-25 New effector conjugates, process for their production and their pharmaceutical use
NO20051038A NO20051038L (no) 2002-07-31 2005-02-25 Nye effektorkonjugater, fremgangsmate for deres fremstilling, og deres farmasoytiske bruk

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE10234975.4 2002-07-31
DE10234975A DE10234975A1 (de) 2002-07-31 2002-07-31 Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
DE10305098A DE10305098A1 (de) 2003-02-07 2003-02-07 Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
DE10305098.1 2003-02-07
US45167303P 2003-03-05 2003-03-05
US60/451,673 2003-03-05

Publications (2)

Publication Number Publication Date
WO2004012735A2 WO2004012735A2 (fr) 2004-02-12
WO2004012735A3 true WO2004012735A3 (fr) 2004-05-27

Family

ID=31498923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008483 WO2004012735A2 (fr) 2002-07-31 2003-07-31 Nouveaux conjugues d'effecteurs, procedes permettant de les produire et utilisation pharmaceutique de ceux-ci

Country Status (16)

Country Link
EP (1) EP1524979A2 (fr)
JP (1) JP2006505627A (fr)
KR (1) KR20050026033A (fr)
AU (1) AU2003253365A1 (fr)
BR (1) BR0313043A (fr)
CA (1) CA2492437A1 (fr)
CO (1) CO5700741A2 (fr)
EC (1) ECSP055626A (fr)
HR (1) HRP20050186A2 (fr)
IL (1) IL166039A0 (fr)
IS (1) IS7708A (fr)
MX (1) MXPA05001282A (fr)
NO (1) NO20051038L (fr)
NZ (1) NZ537870A (fr)
PL (1) PL374528A1 (fr)
WO (1) WO2004012735A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161430A2 (fr) * 1999-02-11 2001-12-12 Schering Aktiengesellschaft Derives d'epothilone, leur procede de production et leur utilisation pharmaceutique
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN1759115A (zh) 2002-08-23 2006-04-12 索隆-基特林癌症研究协会 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途
GB0221312D0 (en) * 2002-09-13 2002-10-23 Novartis Ag Organic compounds
DE10256982A1 (de) 2002-12-05 2004-06-24 Schering Ag Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung
JP2006510626A (ja) * 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト 増殖疾患の処理における部位特異的供給のためのエポチロン類似体
DE602005003453T2 (de) * 2004-01-30 2008-09-25 Bayer Schering Pharma Aktiengesellschaft Neue effektor-konjugate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
AR061181A1 (es) 2006-05-25 2008-08-13 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
PE20080102A1 (es) * 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
EP2152717A1 (fr) 2007-05-25 2010-02-17 Bristol-Myers Squibb Company Procedes de fabrication de composes et d'analogues d'epothilone
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
IT1401451B1 (it) * 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
MX2019004434A (es) * 2016-10-17 2019-09-26 Pfizer Anticuerpos anti-edb y conjugados anticuerpo-fármaco.
KR102377416B1 (ko) * 2017-06-30 2022-03-21 엘지디스플레이 주식회사 표시장치

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0121350A2 (fr) * 1983-03-07 1984-10-10 Smithkline Beckman Corporation Acides mercaptocarboxyliques insaturés substitués et dérivés comme antagonistes de leukotriène
WO1994011021A1 (fr) * 1992-11-10 1994-05-26 Cortech, Inc. Antagoniste de bradykinine
US5942555A (en) * 1996-03-21 1999-08-24 Surmodics, Inc. Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom
WO2001064650A2 (fr) * 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues
WO2001083800A2 (fr) * 2000-04-28 2001-11-08 Kosan Biosciences, Inc. Production de polyketides
EP1156053A2 (fr) * 2000-05-18 2001-11-21 National Starch and Chemical Investment Holding Corporation Silanes avec des groupements carbamates ou uréa, et des groupements avec une fonctionnalité de donneur ou accepteur
WO2001092255A2 (fr) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Derives d'epothilone, procedes de production et methodes d'utilisation
DE10041221A1 (de) * 2000-08-22 2002-03-14 Deutsches Krebsforsch Verfahren zur Herstellung von wasserlöslichen Saccharidkonjugaten und Saccharidmimetika durch Diels-Alder-Reaktion und ihre Verwendung als Therapeutika oder Diagnostika
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
WO2003005026A2 (fr) * 2001-07-02 2003-01-16 Amersham Biosciences Uk Limited Reactif chimique de capture

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0121350A2 (fr) * 1983-03-07 1984-10-10 Smithkline Beckman Corporation Acides mercaptocarboxyliques insaturés substitués et dérivés comme antagonistes de leukotriène
WO1994011021A1 (fr) * 1992-11-10 1994-05-26 Cortech, Inc. Antagoniste de bradykinine
US5942555A (en) * 1996-03-21 1999-08-24 Surmodics, Inc. Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
WO2001064650A2 (fr) * 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues
WO2001083800A2 (fr) * 2000-04-28 2001-11-08 Kosan Biosciences, Inc. Production de polyketides
EP1156053A2 (fr) * 2000-05-18 2001-11-21 National Starch and Chemical Investment Holding Corporation Silanes avec des groupements carbamates ou uréa, et des groupements avec une fonctionnalité de donneur ou accepteur
WO2001092255A2 (fr) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Derives d'epothilone, procedes de production et methodes d'utilisation
DE10041221A1 (de) * 2000-08-22 2002-03-14 Deutsches Krebsforsch Verfahren zur Herstellung von wasserlöslichen Saccharidkonjugaten und Saccharidmimetika durch Diels-Alder-Reaktion und ihre Verwendung als Therapeutika oder Diagnostika
WO2003005026A2 (fr) * 2001-07-02 2003-01-16 Amersham Biosciences Uk Limited Reactif chimique de capture

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERSUKER I B ET AL: "Improved electron-conformational method of pharmacophore identification and bioactivity prediction. Application to angiotensin converting enzyme inhibitors.", JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES. 2000 NOV-DEC, vol. 40, no. 6, November 2000 (2000-11-01), pages 1363 - 1376, XP002274169, ISSN: 0095-2338 *
KALGUTKAR A S ET AL: "Inactivation of prostaglandin endoperoxide synthase (PGHS) by N-(substituted)maleimides.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 1997, vol. 407, 1997, pages 79 - 85, XP009027572, ISSN: 0065-2598 *
REGHUNADHAN NAIR C P ET AL: "Free radical copolymerisation of N-(4-hydroxy phenyl) maleimide with vinyl monomers: Solvent and penultimate-unit effects", EUROPEAN POLYMER JOURNAL, PERGAMON PRESS LTD. OXFORD, GB, vol. 35, no. 10, 28 July 1999 (1999-07-28), pages 1829 - 1840, XP004179475, ISSN: 0014-3057 *
WANG LAI-XI ET AL: "Carbohydrate-centered maleimide cluster as a new type of templates for multivalent peptide assembling: Synthesis of multivalent HIV-1 gp41 peptides.", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 11, no. 1, 2 January 2003 (2003-01-02), &, pages 159 - 166, XP002274170, ISSN: 0968-0896 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof

Also Published As

Publication number Publication date
MXPA05001282A (es) 2005-04-28
BR0313043A (pt) 2005-06-14
ECSP055626A (es) 2005-04-18
JP2006505627A (ja) 2006-02-16
EP1524979A2 (fr) 2005-04-27
NZ537870A (en) 2007-03-30
IS7708A (is) 2005-02-23
KR20050026033A (ko) 2005-03-14
CO5700741A2 (es) 2006-11-30
PL374528A1 (en) 2005-10-31
NO20051038L (no) 2005-04-06
IL166039A0 (en) 2006-01-15
HRP20050186A2 (en) 2005-10-31
WO2004012735A2 (fr) 2004-02-12
CA2492437A1 (fr) 2004-02-12
AU2003253365A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
WO2004012735A3 (fr) Nouveaux conjugues d'effecteurs, procedes permettant de les produire et utilisation pharmaceutique de ceux-ci
WO2005074901A3 (fr) Nouveaux conjugues d'effecteurs, leurs procedes de production et leur utilisation pharmaceutique
RS20050082A (en) New efector conjugates,process for their production and their pharmaceutical use
WO2003008431A1 (fr) Methode de production d'un derive d'asparagine de chaines des sucres
AU2003242083A1 (en) Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
EP1726299A3 (fr) Noyaux et microcapsules pour l' administration parenterale et procédé pour leur fabrication
AU2003282094A1 (en) Novel dihydroxy-methylphenyl derivatives, method for the production and use thereof as medicaments
WO2003018022A8 (fr) Derives de 2-amino-4-heteroarylaminopyrimidine pouvant etre utilises pour traiter le cancer
MXPA03012013A (es) Derivados de 1-oxa-2,8-diaza-spiro[4,5]dec-2-eno sustituidos como medicamento para el tratamiento de dolor.
WO2006059103A3 (fr) Composes
HK1070350A1 (en) Protected 3.5-dihydroxy-2.2-dimethyl-valeronitriles for the synthesis of epothilones and derivatives and method for the production and use thereof
WO2003026563A3 (fr) Antipsychotiques conjugues et utilisations de ceux-ci
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
WO2002074036A3 (fr) Benzopyranones substitues utilises en tant qu'inhibiteurs de telomerase
WO2004111047A3 (fr) Cycloalkanepyrrolopyridines utilisees comme antagonistes du recepteur dp
AU2003903242A0 (en) Process for the treatment of wood
TW200603215A (en) Apparatus for manufacturing substrate
AU7280300A (en) Porous organic polymer shaped bodies
AU2003228202A1 (en) Process for the production of nanoparticles, wherein low mechanical and sonic energies are used simultaneously
TW200510323A (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
AU2002358768A1 (en) Organic dispersions of surface-modified nanoparticles, method for the production and use thereof
WO2005021541A3 (fr) Processus
NO20051794D0 (no) Fremgangsmate for fremstilling av epotilonderivater, og nye mellomprodukter for fremgangsmaten, samt fremgangsmater for fremstilling av slike
BRPI0415529A (pt) derivados de bengamida, processos para produção dos mesmos e uso dos mesmos para tratamento de doenças cancerosas
WO2004033416A3 (fr) Derives d'acyl-carboxyphenyl-uree a substitution carboxyalcoxy, leur procede de production et leur utilisation en tant que medicament

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0082

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003743752

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 38/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2492437

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 537870

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005506073

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038181118

Country of ref document: CN

Ref document number: 1-2005-500185

Country of ref document: PH

Ref document number: 1020057001569

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001282

Country of ref document: MX

Ref document number: 2003253365

Country of ref document: AU

Ref document number: 374528

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: CR2005-007674

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 200500223

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2005/01648

Country of ref document: ZA

Ref document number: 05017568

Country of ref document: CO

Ref document number: 200501648

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: P20050186A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 1020057001569

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003743752

Country of ref document: EP